Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer

Matteo Lambertini, Lucia Del Mastro, Giulia Viglietti, Noam F. Pondé, Cinzia Solinas, Evandro De Azambuja

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years. Recently, several studies have provided important insights on the role of OFS. Currently, the use of tamoxifen alone without prior cytotoxic therapy can be considered a very effective treatment option in young patients with hormone receptor-positive breast cancer at low risk of relapse. On the other hand, for patients at higher risk of relapse as those who are candidates to (neo)adjuvant chemotherapy, OFS proved to be beneficial, and therefore luteinizing hormone-releasing hormone agonists (LHRHa) should be considered in addition to tamoxifen or aromatase inhibitors (AI). However, toxicity is considerable and patients should be actively engaged in decision-making. Finally, in young breast cancer patients who are candidates to (neo)adjuvant chemotherapy, loss of ovarian function and fertility may be a concern. Besides other techniques, recent results showed that temporary OFS with LHRHa during cytotoxic treatment can be considered a reliable strategy to preserve gonadal function and fertility. Despite the recent advances in the field, several gray zones remain unanswered: the role of OFS plus AI in women who remained premenopausal after 5 years of tamoxifen, the optimal extended approach in women treated with 5 years of OFS plus AI, and the role of temporary OFS with LHRHa during chemotherapy in the specific subgroup of patients with BRCA mutations and in women undergoing this strategy after prior embryo/oocyte cryopreservation.

Original languageEnglish
Article number4
JournalCurrent Treatment Options in Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Breast Neoplasms
Aromatase Inhibitors
Tamoxifen
Gonadotropin-Releasing Hormone
Adjuvant Chemotherapy
Drug Therapy
Fertility
Therapeutics
Hormones
Recurrence
Cryopreservation
Amenorrhea
Oocytes
Decision Making
Embryonic Structures
Mutation
Neoplasms

Keywords

  • Adjuvant endocrine therapy
  • Breast cancer
  • Fertility preservation
  • LHRHa
  • Ovarian function suppression
  • Premenopausal patients
  • Young patients

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. / Lambertini, Matteo; Del Mastro, Lucia; Viglietti, Giulia; Pondé, Noam F.; Solinas, Cinzia; De Azambuja, Evandro.

In: Current Treatment Options in Oncology, Vol. 18, No. 1, 4, 01.01.2017.

Research output: Contribution to journalReview article

Lambertini, Matteo ; Del Mastro, Lucia ; Viglietti, Giulia ; Pondé, Noam F. ; Solinas, Cinzia ; De Azambuja, Evandro. / Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. In: Current Treatment Options in Oncology. 2017 ; Vol. 18, No. 1.
@article{6cebdaa099d9403b99140fa13c42117b,
title = "Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer",
abstract = "Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years. Recently, several studies have provided important insights on the role of OFS. Currently, the use of tamoxifen alone without prior cytotoxic therapy can be considered a very effective treatment option in young patients with hormone receptor-positive breast cancer at low risk of relapse. On the other hand, for patients at higher risk of relapse as those who are candidates to (neo)adjuvant chemotherapy, OFS proved to be beneficial, and therefore luteinizing hormone-releasing hormone agonists (LHRHa) should be considered in addition to tamoxifen or aromatase inhibitors (AI). However, toxicity is considerable and patients should be actively engaged in decision-making. Finally, in young breast cancer patients who are candidates to (neo)adjuvant chemotherapy, loss of ovarian function and fertility may be a concern. Besides other techniques, recent results showed that temporary OFS with LHRHa during cytotoxic treatment can be considered a reliable strategy to preserve gonadal function and fertility. Despite the recent advances in the field, several gray zones remain unanswered: the role of OFS plus AI in women who remained premenopausal after 5 years of tamoxifen, the optimal extended approach in women treated with 5 years of OFS plus AI, and the role of temporary OFS with LHRHa during chemotherapy in the specific subgroup of patients with BRCA mutations and in women undergoing this strategy after prior embryo/oocyte cryopreservation.",
keywords = "Adjuvant endocrine therapy, Breast cancer, Fertility preservation, LHRHa, Ovarian function suppression, Premenopausal patients, Young patients",
author = "Matteo Lambertini and {Del Mastro}, Lucia and Giulia Viglietti and Pond{\'e}, {Noam F.} and Cinzia Solinas and {De Azambuja}, Evandro",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s11864-017-0442-8",
language = "English",
volume = "18",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer

AU - Lambertini, Matteo

AU - Del Mastro, Lucia

AU - Viglietti, Giulia

AU - Pondé, Noam F.

AU - Solinas, Cinzia

AU - De Azambuja, Evandro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years. Recently, several studies have provided important insights on the role of OFS. Currently, the use of tamoxifen alone without prior cytotoxic therapy can be considered a very effective treatment option in young patients with hormone receptor-positive breast cancer at low risk of relapse. On the other hand, for patients at higher risk of relapse as those who are candidates to (neo)adjuvant chemotherapy, OFS proved to be beneficial, and therefore luteinizing hormone-releasing hormone agonists (LHRHa) should be considered in addition to tamoxifen or aromatase inhibitors (AI). However, toxicity is considerable and patients should be actively engaged in decision-making. Finally, in young breast cancer patients who are candidates to (neo)adjuvant chemotherapy, loss of ovarian function and fertility may be a concern. Besides other techniques, recent results showed that temporary OFS with LHRHa during cytotoxic treatment can be considered a reliable strategy to preserve gonadal function and fertility. Despite the recent advances in the field, several gray zones remain unanswered: the role of OFS plus AI in women who remained premenopausal after 5 years of tamoxifen, the optimal extended approach in women treated with 5 years of OFS plus AI, and the role of temporary OFS with LHRHa during chemotherapy in the specific subgroup of patients with BRCA mutations and in women undergoing this strategy after prior embryo/oocyte cryopreservation.

AB - Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years. Recently, several studies have provided important insights on the role of OFS. Currently, the use of tamoxifen alone without prior cytotoxic therapy can be considered a very effective treatment option in young patients with hormone receptor-positive breast cancer at low risk of relapse. On the other hand, for patients at higher risk of relapse as those who are candidates to (neo)adjuvant chemotherapy, OFS proved to be beneficial, and therefore luteinizing hormone-releasing hormone agonists (LHRHa) should be considered in addition to tamoxifen or aromatase inhibitors (AI). However, toxicity is considerable and patients should be actively engaged in decision-making. Finally, in young breast cancer patients who are candidates to (neo)adjuvant chemotherapy, loss of ovarian function and fertility may be a concern. Besides other techniques, recent results showed that temporary OFS with LHRHa during cytotoxic treatment can be considered a reliable strategy to preserve gonadal function and fertility. Despite the recent advances in the field, several gray zones remain unanswered: the role of OFS plus AI in women who remained premenopausal after 5 years of tamoxifen, the optimal extended approach in women treated with 5 years of OFS plus AI, and the role of temporary OFS with LHRHa during chemotherapy in the specific subgroup of patients with BRCA mutations and in women undergoing this strategy after prior embryo/oocyte cryopreservation.

KW - Adjuvant endocrine therapy

KW - Breast cancer

KW - Fertility preservation

KW - LHRHa

KW - Ovarian function suppression

KW - Premenopausal patients

KW - Young patients

UR - http://www.scopus.com/inward/record.url?scp=85011999501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011999501&partnerID=8YFLogxK

U2 - 10.1007/s11864-017-0442-8

DO - 10.1007/s11864-017-0442-8

M3 - Review article

VL - 18

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

M1 - 4

ER -